MACÊDO, D. B. R.; MEDEIROS, I. T. G.; http://lattes.cnpq.br/8841232550810913; http://lattes.cnpq.br/9973105493087351; MACÊDO, Daniela Borges da Rocha.; MEDEIROS, Izanny Theresa Galvão de.
Resumo:
Among the chemotherapy complications, peripheral chemotherapy-induced
neuropathy (CIPN) is the most common neurological syndrome secondary to cancer therapy
and may have a profound impact on quality of life and the possibility to adversely affect cancer
outcomes. Objectives: To identify risk factors for peripheral neuropathy in cancer patients
undergoing chemotherapy outpatients followed at Hospital Universitário Alcides Carneiro
(HUAC) and Fundação Assistencial da Paraíba (FAP). Methods: This was an analytical crosssectional
observational uncontrolled study with a sample of 102 patients treated with
chemotherapy. The combination of patient characteristics and the chemotherapy regimen with
the presence of peripheral neuropathy measured by LANSS scale. For it used the χ2 test
association and Fisher's exact test, when necessary, considering the significance level of 5%.
To determine the strength of association, calculated the odds ratio (OR) and its confidence
interval of 95% (95%). Results: It was found that the use of chemotherapy alone the nitrogen
mustards classes and antitumor antibiotics is shown as a risk factor for the development of
peripheral neuropathy (OR: 3.74; 95% CI: 1.24 to 11.24 / OR : 3.13; 95% CI: 1.5 to 9.34
respectively), but after multiple logistic regression showed that association not static
significance. Discussion: The prevalence of neuropathic pain in the sample is 15.7%. Risk
factors associated with the development of pain likely neuropathic (SLANSS≥12) identified in
our sample were the use of nitrogen mustards and antitumor antibiotics. However, after multiple
logistic regression hierarchic this association did not persist with statistical significance in the
final model. Conclusion: The prevalence of peripheral neuropathy induced by chemotherapy
proved compatible with the assessed literature. Taken together they were not presented risk or
protective factors for the development of CIPN.